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Evaluation of the Overall Binding of Acetohexamide and Tolbutamide with Methyl Glyoxal-Modified HSA 
by High Performance Affinity Chromatography
Ashley G. Woolfork and David S. Hage
Department of Chemistry, University of Nebraska – Lincoln, Lincoln, NE 68588-0304
• In 2017, approximately 425 million adults
worldwide were living with diabetes.[1] This number
is rapidly increasing and is projected to affect 629
million individuals by 2045. [2]
• Diabetes is a disease that is associated with
elevated levels of glucose in the bloodstream,
resulting in nonenzymatic protein glycation,
illustrated in Figure 2.[3]
• Human serum albumin (HSA), pictured in Figure 1,
is the most abundant transport protein in serum
with two major drug binding sites (Sudlow sites I
and II) and is involved in several physiological
processes. [4]
• Sulfonylurea drugs are orally administered drugs
that are commonly used to treat type II diabetes
and are known to bind tightly to serum proteins,
especially HSA.[5]
• Individuals living with diabetes have approximately
20-30% more of their HSA in a glycated form. This
can result in modification at both Sudlow sites, thus
leading to possible changes in the binding of
sulfonylurea drugs. [5]
• The goal of this study is to examine the overall
binding of two sulfonylurea drugs with normal HSA
vs methyl glyoxal modified-HSA.
Introduction
Figure 1. The structure of human serum albumin. The major
binding sites on HSA bind bulky and heterocyclic drugs such as
R-warfarin (Sudlow site I) and aromatic compounds such as L-
tryptophan (Sudlow site II).
Figure 4. Structures of sulfonylurea drugs examined: acetohexamide (a) and
tolbutamide (b).
Methods
Figure 5. A typical chromatogram for injection of a single concentration of drug
with a site-specific probe. This chromatogram represents 10 μM of tolbutamide
with the R-warfarin probe where the dashed line represents the retention time of
the probe in the absence of drug (a). The linear plot describing the direct
competition between the probe and competition drug at a single site, as described
by equation 1. This plot represents tolbutamide competition with the R-Warfarin
probe (b).
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• The site-specific association equilibrium constants for acetohexamide and
tolbutamide were determined for normal HSA and control and diabetic MGo-
modified HSA, Tables 1 and 2.
• An approximate 0.4-fold to 0.8-fold decrease in binding was found when
comparing normal HSA vs control MGo-modified HSA and normal HSA vs
diabetic MGo-modified HSA, respectively, shown in Figure 6.
• HPAC zonal competition method was demonstrated as a faster, alterative
approach for studying drug-protein interactions over other techniques such
as frontal analysis.
Table 1. The site-specific association equilibrium constants for normal HSA, control MGo-
modified HSA, and diabetic MGo-modified HSA where the R-Warfarin probe was employed.
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Figure 2. The process of early stage glycation and advanced
glycation. Glucose reacts with a free amine group on a protein
to form a reversible Schiff base which can then be rearranged to
a more stable Amadori product, also known as glycated HSA.
Through other pathways such as oxidation, dehydration, and
degradation, glycated HSA yields advanced glycation end-
products (AGEs).
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Chromatographic Results
Figure 3. Method of separation for high-performance affinity chromatography
(HPAC).
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• Drug solutions were injected onto 10 mm x 2.1 mm i.d. affinity
microcolumns containing normal HSA and HSA modified with
methylglyoxal (MGo), as can occur in controlled and advanced
diabetes.
• Chromatographic experiments were carried out at a flow rate of
0.5 mL/min and at a temperature of 37 °C.
• The competition studies based on zonal elution were carried out
using R-warfarin as a site-specific probe for Sudlow site I and L-
tryptophan as a site-specific probe for Sudlow site II.
• These studies were performed with eight different concentrations
of acetohexamide and tolbutamide in the mobile phase, spanning
from 0 to 25 μM. The same solutions of the drugs were used to
make samples of the desired probe at a concentration of 5 µM.
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Table 1. Ka for Drugs at Sudlow Site I
Acetohexamide ( x 104 M-1) Tolbutamide ( x 104 M-1)
Normal HSA 4.20 (±0.1) 5.50 (±0.04)
Control Methyl Glyoxal HSA 1.62 (±0.2) 4.05 (±0.1) 
Diabetic Methyl Glyoxal HSA 5.76 (±0.1) 3.81 (±0.1) 
Table 2. Ka for Drugs at Sudlow Site II
Acetohexamide ( x 104 M-1) Tolbutamide ( x 104 M-1)
Normal HSA 13.0 (±0.1) 5.30 (±0.04)
Control Methyl Glyoxal HSA 7.53 (±0.1) 4.58 (±0.1) 
Diabetic Methyl Glyoxal HSA 1.26 (±0.2) 3.92 (±0.06) 
Table 2. The site-specific association equilibrium constants for normal HSA, control MGo-
modified HSA, and diabetic MGo-modified HSA for the L-Tryptophan probe.
Figure 6. Changes in the binding of drugs when comparing control MGo-modified HSA vs
normal HSA (dark grey) and diabetic MGo-modified HSA vs normal HSA (light grey).
Eq. 1. Equation used to calculate association equilibrium constant 
where k: retention factor, KaA and KaP: association equilibrium 
constant for the analyte and probe at the competition site, [A]: 
concentration of analyte, VM: void volume, and mL: moles of 
common binding sites 
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